PUBLISHER: The Business Research Company | PRODUCT CODE: 1889543
PUBLISHER: The Business Research Company | PRODUCT CODE: 1889543
Precision psychiatry is a data driven approach that integrates genetic, neurobiological, behavioral, and environmental information to understand individual disease mechanisms. Its primary goal is to improve diagnostic accuracy, guide personalized treatment, and enhance outcomes by minimizing trial and error in prescribing. It also supports preventive strategies through personalized risk assessment and continuous monitoring.
The main therapeutic approaches in precision psychiatry include pharmacotherapy, psychotherapy, neurostimulation, digital therapeutics, and combination therapies. Pharmacotherapy in precision psychiatry refers to the use of personalized medication plans based on an individual's genetic, biochemical, and clinical profile to manage mental health disorders. It employs various technologies such as genetic testing, biomarker analysis, brain imaging techniques, wearable devices, and artificial intelligence and machine learning solutions, and is indicated for conditions including depression, anxiety disorders, bipolar disorder, schizophrenia, and post traumatic stress disorder (PTSD). It is applied in diagnosis, treatment, and research, serving end users such as clinics, hospitals, research institutes, pharmaceutical companies, and home care settings.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The precision psychiatry market research report is one of a series of new reports from The Business Research Company that provides precision psychiatry market statistics, including precision psychiatry industry global market size, regional shares, competitors with a precision psychiatry market share, detailed precision psychiatry market segments, market trends and opportunities, and any further data you may need to thrive in the precision psychiatry industry. This precision psychiatry market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The precision psychiatry market size has grown rapidly in recent years. It will grow from $4.34 billion in 2024 to $4.99 billion in 2025 at a compound annual growth rate (CAGR) of 14.9%. The growth in the historic period can be attributed to rising adoption of digital health tools, growing investment in psychiatric research, expansion of neuroimaging facilities, increasing focus on personalized treatment, and rising demand for remote monitoring solutions.
The precision psychiatry market size is expected to see rapid growth in the next few years. It will grow to $8.58 billion in 2029 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to increasing adoption of wearable biosensors, growing collaborations between biotech and healthcare providers, expansion of telepsychiatry platforms, rising funding for precision psychiatry startups, and increasing use of genetic testing in mental health assessment. Major trends in the forecast period include technological advancements in digital therapeutics, developments in neuroimaging and biomarker analysis, investment in research and development of personalized psychiatric treatments, innovation in cognitive assessment tools, and technological progress in remote patient monitoring.
The increasing prevalence of mental health disorders is expected to drive the growth of the precision psychiatry market in the coming years. Mental health disorders encompass a wide range of conditions, including depression, anxiety, and bipolar disorder, which impact mood, thinking, and behavior. The rise in mental health disorders is attributed to growing psychological distress from social, economic, and environmental pressures, along with improved screening and public awareness that contribute to higher diagnosis rates. Precision psychiatry addresses these disorders by providing data-driven, personalized treatment strategies that enhance diagnostic accuracy and therapeutic outcomes. For instance, in November 2023, according to NHS England, the UK based publicly funded national health authority, the rate of probable mental disorders among individuals aged 20 to 23 increased from 18.7 percent in 2022 to 21.6 percent in 2023. Therefore, the growing prevalence of mental health disorders is driving the expansion of the precision psychiatry market.
Major companies in the precision psychiatry market are developing new therapies such as prescription digital therapeutics to enable personalized, data-driven treatment for psychiatric conditions. A prescription digital therapeutic is a clinician-prescribed, software-based medical intervention that delivers evidence-based behavioral therapy modules through a mobile device to improve symptom management and treatment adherence. For example, in August 2024, Otsuka Precision Health Inc., a US based precision health subsidiary of Otsuka Holdings, and Click Therapeutics Inc., a US based digital therapeutics company, launched Rejoyn, the first prescription digital therapeutic cleared by the United States Food and Drug Administration (FDA) for adjunctive treatment of major depressive disorder symptoms. The product provides a six-week cognitive-emotional training program combining the emotional faces memory task with cognitive behavioral therapy based skill modules and supports digital prescribing, patient engagement, and remote monitoring. The launch of Rejoyn represents a key milestone in precision psychiatry, demonstrating how digital therapeutics can complement pharmacological treatments to deliver personalized care. It also supports broader adoption of software-based interventions that integrate real-time patient data to optimize treatment outcomes and adherence.
In January 2025, Johnson and Johnson, a US based pharmaceutical company, acquired Intra-Cellular Therapies Inc. for approximately $14.6 billion. Through this acquisition, Johnson and Johnson aims to expand its portfolio of innovative psychiatric therapies and leverage Intra-Cellular's expertise in mechanism-based drug development for central nervous system disorders. Intra-Cellular Therapies Inc. is a US based company focused on developing targeted neuropsychiatric therapies aligned with precision psychiatry.
Major companies operating in the precision psychiatry market are Johnson & Johnson, F. Hoffmann-La Roche Ltd, Pfizer Inc., AbbVie Inc., AstraZeneca plc, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Eli Lilly and Company, Otsuka Pharmaceutical Company Limited, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Illumina Inc., ARUP Laboratories Inc., Sumitomo Dainippon Pharma Company Limited, QIAGEN N.V., Neurocrine Biosciences Inc., Tempus Labs Inc., Myriad Genetics Inc., MedGenome Labs Ltd., Genomind Inc., STALICLA SA
North America was the largest region in the precision psychiatry market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in precision psychiatry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the precision psychiatry market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The precision psychiatry market includes revenues earned by entities through psychiatric assessment, personalized treatment planning, remote monitoring, data analytics, and clinical decision support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Precision Psychiatry Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on precision psychiatry market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for precision psychiatry ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The precision psychiatry market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.